| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Qiang Ma | Q79935556 |
| P2093 | author name string | A. Y. H. Lu | |
| P2860 | cites work | Origins of individual variability in P4501A induction | Q23919659 |
| From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions | Q60670847 | ||
| Common allelic variants of cytochrome P4503A4 and their prevalence in different populations | Q63241958 | ||
| The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day | Q73048669 | ||
| MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects | Q77133730 | ||
| Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research | Q77221152 | ||
| CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans | Q77788807 | ||
| Genetic control of isoniazid metabolism in man | Q79227074 | ||
| Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment | Q79826393 | ||
| Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2) | Q81235097 | ||
| Pharmacogenomics of 4-hydroxycoumarin anticoagulants | Q81235099 | ||
| Warfarin pharmacogenetics | Q81887452 | ||
| The challenges of dealing with promiscuous drug-metabolizing enzymes, receptors and transporters | Q25112732 | ||
| Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib | Q27861059 | ||
| A common polymorphism associated with antibiotic-induced cardiac arrhythmia | Q28138550 | ||
| Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype | Q28140057 | ||
| Human UDP-glucuronosyltransferases: metabolism, expression, and disease | Q28145608 | ||
| Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction | Q28168881 | ||
| Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics | Q28179830 | ||
| A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms | Q28203288 | ||
| Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans | Q28209488 | ||
| Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity | Q28218156 | ||
| Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives | Q28222158 | ||
| Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 | Q28242581 | ||
| Identification of the gene for vitamin K epoxide reductase | Q28242592 | ||
| Medical genetics: a marker for Stevens-Johnson syndrome | Q28254047 | ||
| HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin | Q29417159 | ||
| Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene | Q29614892 | ||
| SLCO1B1 variants and statin-induced myopathy--a genomewide study | Q29619028 | ||
| Some statistical data on atypical cholinesterase of human serum | Q30874133 | ||
| Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. | Q32072529 | ||
| Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein | Q33267448 | ||
| Apixaban metabolism and pharmacokinetics after oral administration to humans | Q33373622 | ||
| Estimation of the warfarin dose with clinical and pharmacogenetic data | Q33410725 | ||
| Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease | Q33662063 | ||
| Pharmacogenomics: translating functional genomics into rational therapeutics | Q33751829 | ||
| TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients. | Q33941873 | ||
| N-acetyltransferase 2 and bladder cancer: an overview and consideration of the evidence for gene-environment interaction | Q33985340 | ||
| A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans | Q34085379 | ||
| Pharmacogenetics and adverse drug reactions | Q34088287 | ||
| Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir | Q34117815 | ||
| Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States | Q34165115 | ||
| Inheritance and drug response | Q34175608 | ||
| Pharmacogenomics--drug disposition, drug targets, and side effects | Q34175616 | ||
| Pharmacogenomics: unlocking the human genome for better drug therapy | Q34192677 | ||
| Interindividual variability in inhibition and induction of cytochrome P450 enzymes | Q34192754 | ||
| Pharmacogenetic study of statin therapy and cholesterol reduction | Q44938097 | ||
| Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype | Q44960521 | ||
| CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori | Q45062165 | ||
| High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives | Q45887974 | ||
| ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. | Q45993642 | ||
| Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. | Q45995789 | ||
| Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. | Q46023319 | ||
| Defective activity of recombinant cytochromes P450 3A4.2 and 3A4.16 in oxidation of midazolam, nifedipine, and testosterone | Q46453447 | ||
| Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics | Q46551880 | ||
| A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance | Q46566220 | ||
| Genetic testing for warfarin dosing? Not yet ready for prime time | Q46787525 | ||
| Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc | Q46868498 | ||
| Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression | Q46906576 | ||
| Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism | Q46980000 | ||
| Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors | Q48206347 | ||
| Richard Weinshilboum: Pharmacogenetics: The future is here! | Q48351049 | ||
| Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. | Q50899702 | ||
| Contrasting Genetic Influence of CCR2 and CCR5 Variants on HIV-1 Infection and Disease Progression | Q56607621 | ||
| Digoxin pharmacokinetics and MDR1 genetic polymorphisms | Q57314091 | ||
| Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males | Q57500331 | ||
| SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid | Q57825144 | ||
| Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy | Q59489273 | ||
| Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids | Q34318910 | ||
| CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment | Q34381754 | ||
| Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity | Q34400003 | ||
| Common VKORC1 and GGCX polymorphisms associated with warfarin dose | Q34417386 | ||
| Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose | Q34423204 | ||
| Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes | Q34477526 | ||
| Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster | Q34502235 | ||
| Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. | Q34502241 | ||
| HLA-B*5701 screening for hypersensitivity to abacavir | Q34747145 | ||
| Association of warfarin dose with genes involved in its action and metabolism | Q35633802 | ||
| Moving towards individualized medicine with pharmacogenomics | Q35784527 | ||
| Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios | Q35860313 | ||
| Pharmacogenomics and individualized drug therapy | Q36366823 | ||
| Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants | Q36525260 | ||
| The pharmocogenomics of warfarin: closing in on personalized medicine | Q36588832 | ||
| Pharmacogenomics: challenges and opportunities | Q36658763 | ||
| Pharmacokinetic and pharmacodynamic variability: a daunting challenge in drug therapy | Q36737738 | ||
| Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues | Q36956360 | ||
| Clinical pharmacogenetics and potential application in personalized medicine | Q37294099 | ||
| Translation of the Philadelphia chromosome into therapy for CML. | Q37344094 | ||
| Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant | Q37356747 | ||
| A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity | Q37380399 | ||
| Targeted cancer therapies in the twenty-first century: lessons from imatinib | Q37710963 | ||
| CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity | Q38315596 | ||
| Pharmacogenetic perspectives gained from twin and family studies | Q38628447 | ||
| Can personalized drug therapy be achieved? A closer look at pharmaco-metabonomics | Q40284428 | ||
| Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. | Q40812511 | ||
| A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury | Q42966589 | ||
| Use of pharmaco-metabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans | Q43150806 | ||
| ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin | Q43174441 | ||
| Personalized medicine, pharmacogenetics, and clopidogrel: unraveling variability of response. | Q43177405 | ||
| In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies | Q43235385 | ||
| A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. | Q43286781 | ||
| Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes | Q43445863 | ||
| The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization | Q43756517 | ||
| Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus | Q44579589 | ||
| Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics | Q44872799 | ||
| The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. | Q44899003 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | manufacturing | Q187939 |
| gene | Q7187 | ||
| toxicology | Q7218 | ||
| pharmacogenomics | Q1152227 | ||
| disease | Q12136 | ||
| P5008 | on focus list of Wikimedia project | Wikimedia–NIOSH collaboration | Q104416361 |
| P304 | page(s) | 437-459 | |
| P577 | publication date | 2011-03-24 | |
| P1433 | published in | Pharmacological Reviews | Q2085079 |
| P859 | sponsor | NIOSH Health Effects Laboratory Division | Q123344455 |
| P1476 | title | Pharmacogenetics, pharmacogenomics, and individualized medicine | |
| P478 | volume | 63 |
| Q90114170 | A Feasibility Study of an Extrusion-Based Fabrication Process for Personalized Drugs |
| Q58762484 | A Metabolomics Approach to Pharmacotherapy Personalization |
| Q28554371 | A Novel Drug-Mouse Phenotypic Similarity Method Detects Molecular Determinants of Drug Effects |
| Q53176750 | A Polymorphism in the Lysyl Oxidase Propeptide Domain Accelerates Carcinogen-induced Cancer. |
| Q48191729 | A Remote Assay for Measuring Canine Platelet Activation and the Inhibitory Effects of Antiplatelet Agents. |
| Q90065644 | A gene-diet interaction-based score predicts response to dietary fat in the Women's Health Initiative |
| Q41691274 | A novel kinase mutation in VEGFR-1 predisposes its αC-helix/activation loop towards allosteric activation: Atomic insights from protein simulation |
| Q39013355 | A one-step imaging assay to monitor cell cycle state and apoptosis in mammalian cells |
| Q34322438 | A systematic comparison and evaluation of high density exon arrays and RNA-seq technology used to unravel the peripheral blood transcriptome of sickle cell disease |
| Q36670740 | A systematic study on drug-response associated genes using baseline gene expressions of the Cancer Cell Line Encyclopedia |
| Q28078890 | Adaptive capabilities and fitness consequences associated with pollution exposure in fish |
| Q36424264 | Adding Genetic Testing to Evidence-Based Guidelines to Determine the Safest and Most Effective Chronic Pain Treatment for Injured Workers |
| Q38245564 | Advancing stem cell therapy from bench to bedside: lessons from drug therapies |
| Q28538389 | An ontology-based, mobile-optimized system for pharmacogenomic decision support at the point-of-care |
| Q36097760 | An update on the Pharmacovigilance Programme of India |
| Q47715776 | Antituberculosis Drug-Induced Adverse Events in the Liver, Kidneys, and Blood: Clinical Profiles and Pharmacogenetic Predictors. |
| Q26864747 | Application of routine electronic health record databases for pharmacogenetic research |
| Q47203284 | Are the Origins of Precision Medicine Found in the Corpus Hippocraticum? |
| Q55058713 | Association of FCER1A genetic polymorphisms with risk for chronic spontaneous urticaria and efficacy of nonsedating H1-antihistamines in Chinese patients. |
| Q39950111 | Association of Genetic Polymorphisms in the VKORC1 and CYP2C9 Genes with Warfarin Dosage in a Group of Kuwaiti Individuals |
| Q38542847 | Asthma Pharmacogenomics: 2015 Update |
| Q38175707 | Biomarkers in rare neuromuscular diseases. |
| Q90248911 | CYP2B6*6 Genotype Specific Differences in Artemether-Lumefantrine Disposition in Healthy Volunteers |
| Q53644957 | CYP2D6 phenotype-specific codeine population pharmacokinetics. |
| Q37503954 | Cell line modeling for systems medicine in cancers (review). |
| Q38671265 | Clinical Trial Design in Juvenile Idiopathic Arthritis |
| Q36808178 | Clinically relevant genetic variants of drug-metabolizing enzyme and transporter genes detected in Thai children and adolescents with autism spectrum disorder |
| Q62674529 | Cloud-Based High Throughput Virtual Screening in Novel Drug Discovery |
| Q39065445 | Combination analysis in genetic polymorphisms of drug-metabolizing enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese population |
| Q34915414 | Cometabolism of microbes and host: implications for drug metabolism and drug-induced toxicity. |
| Q41078615 | Comparative analysis between saliva and buccal swabs as source of DNA: lesson from HLA-B*57:01 testing. |
| Q35923793 | Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers |
| Q36487348 | Correlation between Gene Variants, Signaling Pathways, and Efficacy of Chemotherapy Drugs against Colon Cancers |
| Q28072203 | Cost-Effectiveness of Pharmacogenomic and Pharmacogenetic Test-Guided Personalized Therapies: A Systematic Review of the Approved Active Substances for Personalized Medicine in Germany |
| Q30971296 | Cypiripi: exact genotyping of CYP2D6 using high-throughput sequencing data |
| Q48310481 | DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer. |
| Q33987606 | Deciphering next-generation pharmacogenomics: an information technology perspective |
| Q30353144 | Differences in the origin of philosophy between Chinese medicine and Western medicine: Exploration of the holistic advantages of Chinese medicine. |
| Q41747771 | Direct PCR: a new pharmacogenetic approach for the inexpensive testing of HLA-B*57:01. |
| Q55315083 | Discovering novel SNPs that are correlated with patient outcome in a Singaporean cancer patient cohort treated with gemcitabine-based chemotherapy. |
| Q24600166 | Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjects |
| Q37715233 | Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective |
| Q35549639 | Distribution of the most Common Genetic Variants Associated with a Variable Drug Response in the Population of the Republic of Macedonia. |
| Q92323624 | Diversity in the Era of Precision Medicine - From Bench to Bedside Implementation |
| Q38899401 | Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy? |
| Q28073025 | Economic Evaluation of Pharmacogenetic Tests in Patients Subjected to Renal Transplantation: A Review of Literature |
| Q33420396 | Effect of GSTP1 and ABCC4 gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-5-fluorouracil-based chemotherapy in Bangladeshi breast cancer patients |
| Q83517464 | Effect of age and gender on pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy individuals |
| Q49557489 | Effectiveness of continuous epidural analgesia on acute herpes zoster and postherpetic neuralgia: A retrospective study. |
| Q35832664 | Electrocatalysis by subcellular liver fractions bound to carbon nanostructures for stereoselective green drug metabolite synthesis. |
| Q64933146 | Enzymatic Activities of CYP3A4 Allelic Variants on Quinine 3-Hydroxylation In Vitro. |
| Q37948826 | Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions. |
| Q35043079 | Evolutionary Diagnosis of non-synonymous variants involved in differential drug response |
| Q38897899 | Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism |
| Q40929491 | Frequencies of EGFR single nucleotide polymorphisms in non-small cell lung cancer patients and healthy individuals in the Republic of Serbia: a preliminary study |
| Q57794673 | Frequencies of poor metabolizer alleles of 12 pharmacogenomic actionable genes in Punjabi Sikhs of Indian Origin |
| Q33683604 | Gene co-expression network analysis identifies porcine genes associated with variation in metabolizing fenbendazole and flunixin meglumine in the liver |
| Q36354529 | Genetic Polymorphisms Analysis of Pharmacogenomic VIP Variants in Miao Ethnic Group of Southwest China. |
| Q38227080 | Genetic markers for prediction of treatment outcomes in ovarian cancer. |
| Q49612685 | Genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in Kosovar population. |
| Q47564586 | Genetic variation in human drug-related genes. |
| Q35638586 | Genetics and tailored therapy in cardiovascular disease |
| Q28554426 | Genome Sequence Variability Predicts Drug Precautions and Withdrawals from the Market |
| Q30795448 | Genome-wide data reveal novel genes for methotrexate response in a large cohort of juvenile idiopathic arthritis cases |
| Q38774369 | Genomic translational research: Paving the way to individualized cardiac functional analyses and personalized cardiology |
| Q44404784 | Genomics and drug discovery |
| Q24282581 | Genomics and the Nature of Behavioral and Social Risk |
| Q38192063 | Global pharmacogenomics: where is the research taking us? |
| Q93068560 | Herbal Remedies: Throwing Off Phenotype Prediction-A Culprit for Pharmacogenomic-Guided Drug Therapy and Drug Safety |
| Q92061917 | High Content Solid Dispersions for Dose Window Extension: A Basis for Design Flexibility in Fused Deposition Modelling |
| Q91843143 | Homogeneity in the association of body mass index with type 2 diabetes across the UK Biobank: A Mendelian randomization study |
| Q34818253 | How informative is the mouse for human gut microbiota research? |
| Q38811685 | How polymorphisms of the cytochrome P450 genes affect ibuprofen and diclofenac metabolism and toxicity |
| Q38874111 | Human Induced Pluripotent Stem Cells as a Platform for Personalized and Precision Cardiovascular Medicine. |
| Q38651234 | Impact of Genetic Polymorphisms on Phenytoin Pharmacokinetics and Clinical Outcomes in the Middle East and North Africa Region. |
| Q30383865 | Impact of germline and somatic missense variations on drug binding sites |
| Q91906258 | Inconsistency in race and ethnic classification in pharmacogenetics studies and its potential clinical implications |
| Q39041940 | Incorporating Pharmacogenomics into Health Information Technology, Electronic Health Record and Decision Support System: An Overview |
| Q33613526 | Increased genetic diversity of ADME genes in African Americans compared with their putative ancestral source populations and implications for pharmacogenomics |
| Q28070574 | Individualization of antiretroviral therapy--pharmacogenomic aspect |
| Q62659072 | Intraethnic variation in steroid-5-alpha-reductase polymorphisms in prostate cancer patients: a potential factor implicated in 5-alpha-reductase inhibitor treatment |
| Q37329568 | Intron 4 VNTR (4a/b) polymorphism of the endothelial nitric oxide synthase gene is associated with breast cancer in Mexican women |
| Q57011994 | Is It Time for a Metagenomic Basis of Therapeutics? |
| Q39096673 | Is there a role for MDR1, EPHX1 and protein Z gene variants in modulation of warfarin dosage? a study on a cohort of the Egyptian population. |
| Q38769814 | Ivabradine for the treatment of chronic heart failure |
| Q35023454 | Lifestyle factors, medication use and risk for ischaemic heart disease hospitalisation: a longitudinal population-based study. |
| Q38497838 | Malaria medicines: a glass half full? |
| Q34615534 | Microbial determinants of biochemical individuality and their impact on toxicology and pharmacology |
| Q35934555 | NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis |
| Q33759731 | Nature, Nurture, and Expertise |
| Q37000847 | Non-synonymous single-nucleotide variations of the human oxytocin receptor gene and autism spectrum disorders: a case-control study in a Japanese population and functional analysis. |
| Q90179100 | Noncoding microRNAs: small RNAs play a big role in regulation of ADME? |
| Q37205614 | Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients: A multicenter study |
| Q37344759 | Omics approaches to individual variation: modeling networks and the virtual patient |
| Q38750137 | Omics for Understanding the Gut-Liver-Microbiome Axis and Precision Medicine |
| Q61811125 | Pathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer Drugs |
| Q30877953 | Patient Characteristics are not Associated with Clinically Important Differential Response to Dapagliflozin: a Staged Analysis of Phase 3 Data |
| Q38976521 | Personalized learning: From neurogenetics of behaviors to designing optimal language training |
| Q38235205 | Personalized medicine approaches for colon cancer driven by genomics and systems biology: OncoTrack |
| Q47095825 | Personalized medicine-a modern approach for the diagnosis and management of hypertension |
| Q52564726 | Personalized skincare: from molecular basis to clinical and commercial applications. |
| Q34234941 | Pharmaco-metabolomics: an emerging "omics" tool for the personalization of anticancer treatments and identification of new valuable therapeutic targets |
| Q48220346 | Pharmacogenetic and pharmacogenomic considerations of asthma treatment. |
| Q36489727 | Pharmacogenetics driving personalized medicine: analysis of genetic polymorphisms related to breast cancer medications in Italian isolated populations |
| Q38078188 | Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective |
| Q47965250 | Pharmacogenetics of aldo-keto reductase 1C (AKR1C) enzymes |
| Q38221179 | Pharmacogenetics of antiretroviral therapy |
| Q38050316 | Pharmacogenetics of nonsteroidal anti-inflammatory drugs |
| Q39204562 | Pharmacogenetics of posttransplant diabetes mellitus |
| Q28088445 | Pharmacogenetics, pharmacogenomics and ayurgenomics for personalized medicine: a paradigm shift |
| Q53066089 | Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer. |
| Q38263127 | Pharmacogenomic biomarker information in FDA-approved paediatric drug labels |
| Q37737731 | Pharmacogenomic implications of the evolutionary history of infectious diseases in Africa |
| Q37893991 | Pharmacogenomics and multiple sclerosis: moving toward individualized medicine. |
| Q27692687 | Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine |
| Q35647167 | Pharmacogenomics of cardiovascular complications in diabetes and obesity |
| Q38857254 | Pharmacogenomics of multifactorial diseases: a focus on psoriatic arthritis. |
| Q57807746 | Pharmacokinetic-Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High-Dose Melphalan for Autologous Stem Cell Transplant |
| Q26748481 | Pharmacometabolomics-aided Pharmacogenomics in Autoimmune Disease |
| Q64060849 | Population Pharmacogenomics for Precision Public Health in Colombia |
| Q90650446 | Prevalence of ABCC3-1767G/A polymorphism among patients with antiretroviral-associated hepatotoxicity |
| Q26852592 | Promise of personalized omics to precision medicine |
| Q112771122 | Querying NeXtProt Nanopublications and Their Value for Insights on Sequence Variants and Tissue Expression |
| Q54670808 | Querying neXtProt nanopublications and their value for insights on sequence variants and tissue expression |
| Q28079207 | Recommendations for Optimizing Tuberculosis Treatment: Therapeutic Drug Monitoring, Pharmacogenetics, and Nutritional Status Considerations |
| Q23923916 | Redox regulation by Nrf2: gatekeeping for the basal and diabetes-induced expression of thioredoxin interacting protein |
| Q37684288 | Smoking and antidepressants pharmacokinetics: a systematic review |
| Q28828464 | Structural characterization of single nucleotide variants at ligand binding sites and enzyme active sites of human proteins |
| Q35803355 | Subgroups of Paediatric Acute Lymphoblastic Leukaemia Might Differ Significantly in Genetic Predisposition to Asparaginase Hypersensitivity |
| Q40405427 | Systematic overview of cost-effectiveness thresholds in ten countries across four continents |
| Q38243205 | Testing for thiopurine methyltransferase status for safe and effective thiopurine administration: a systematic review of clinical guidance documents |
| Q30916493 | The Genotype-Tissue Expression (GTEx) Project: Linking Clinical Data with Molecular Analysis to Advance Personalized Medicine |
| Q47837577 | The Value of Evidence in the Decision-Making Process for Reimbursement of Pharmacogenetic Dosing of Warfarin |
| Q89640506 | The analysis of pharmacokinetic and pharmacogenomic impact on gefitinib efficacy in advanced non-small cell lung cancer patients: results from a prospective cohort study |
| Q41839243 | The context of prostate cancer genomics in personalized medicine |
| Q38020959 | The genetics of multiple sclerosis: an up-to-date review |
| Q40569531 | The impact of CYP2C19 polymorphisms on citalopram metabolism in patients with major depressive disorder |
| Q40222201 | The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum. |
| Q40225108 | The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes |
| Q38122099 | The pharmacology of novel oral anticoagulants |
| Q42792319 | The read-across hypothesis and environmental risk assessment of pharmaceuticals. |
| Q38856712 | The role of drug profiles as similarity metrics: applications to repurposing, adverse effects detection and drug-drug interactions |
| Q39334739 | Thiopurine S-Methyltransferase as a Pharmacogenetic Biomarker: Significance of Testing and Review of Major Methods. |
| Q38188290 | Translational insight into statin-induced muscle toxicity: from cell culture to clinical studies. |
| Q35675094 | Treatment of β-Thalassemia/Hemoglobin E with Antioxidant Cocktails Results in Decreased Oxidative Stress, Increased Hemoglobin Concentration, and Improvement of the Hypercoagulable State |
| Q31009476 | Updates on drug-target network; facilitating polypharmacology and data integration by growth of DrugBank database. |
| Q36382520 | Using activation status of signaling pathways as mechanism-based biomarkers to predict drug sensitivity |
| Q92840253 | Utility of genetic variants to predict prognosis in coronary artery disease patients receiving statin treatment |
| Q38090712 | Utilization of glutathione S-transferase Mu 1- and Theta 1-null mice as animal models for absorption, distribution, metabolism, excretion and toxicity studies |
| Q53566952 | Validation of a fast and low-cost alkaline lysis method for gDNA extraction in a pharmacogenetic context. |
| Q47439130 | Variation in DNA-Damage Responses to an Inhalational Carcinogen (1,3-Butadiene) in Relation to Strain-Specific Differences in Chromatin Accessibility and Gene Transcription Profiles in C57BL/6J and CAST/EiJ Mice |
| Q93224302 | Warfarin maintenance dose associated with genetic polymorphisms of CYP2C9 |
| Q34651200 | Whole brain approaches for identification of microstructural abnormalities in individual patients: comparison of techniques applied to mild traumatic brain injury |
| Q28554445 | Xenobiotic Metabolism and Gut Microbiomes |
| Q28554117 | ePGA: A Web-Based Information System for Translational Pharmacogenomics |
| Q37649634 | mTOR pathway in colorectal cancer: an update |
Search more.